Gilead obtains FDA approval for expanded indication of single tablet HIV-1 regimen Complera

Gilead Sciences has received approval from the US Food and Drug Administration (FDA) for its once-daily single tablet HIV-1 regimen Complera, for use in certain virologically suppressed adult patients on a stable antiretroviral regimen to replace the…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news